Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medtronic Cardiovascular
The study is a prospective, multi-center, non-randomized trial to evaluate the safety and performance of the Twelve TMVR System in very high risk patients with severe, symptomatic mitral regurgitation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Severe mitral regurgitation (MR Grade 3-4+)
Symptomatic mitral regurgitation (NYHA Class II-IV)
Trans-apical access deemed feasible by the treating physician
Native mitral valve geometry and size compatible with the Twelve TMVR
You may not be if
Left ventricular ejection fraction (LVEF) \< 20
Evidence of intracardiac mass, thrombus, or vegetation
Prior valve surgery or need for other valve surgery